Can a Nek­tar ri­val make it on Nas­daq with a $100M IPO? Syn­thorx is giv­ing it a shot

Af­ter all the hub­bub around Nek­tar’s sec­ond-gen take on a pe­gy­lat­ed IL-2, is Nas­daq ready for a ri­val that be­lieves it can do the whole field one bet­ter?

Syn­thorx, a pre­clin­i­cal biotech with pri­mate da­ta that was set up by Aval­on, has filed for a $100 mil­lion IPO — hop­ing to catch a wave of ex­cite­ment that has pro­pelled scores of S-1s this year for ear­ly-stage com­pa­nies.

Like Nek­tar, Syn­thorx start­ed out with the knowl­edge that Pro­leukin nev­er lived up to its in­cred­i­ble ini­tial promise in can­cer, large­ly be­cause of a bad tox pro­file high­light­ed by vas­cu­lar leak syn­drome. And the lit­tle biotech has been work­ing on its own al­ter­na­tive un­der the guid­ance of CEO Lau­ra Shawver, an ex­pe­ri­enced biotech vet.

Here’s the rel­e­vant sec­tion from the S-1 filed with the SEC:

Us­ing our Ex­pand­ed Ge­net­ic Al­pha­bet plat­form tech­nol­o­gy, we site-specif­i­cal­ly pe­gy­lat­ed IL-2 to in­vent THOR-707 for im­muno-on­col­o­gy, or IO. We have de­signed THOR-707 to kill tu­mor cells by in­creas­ing CD8+ T and NK cells with­out caus­ing VLS (vas­cu­lar leak syn­drome) that has been ob­served with aldesleukin. In our non-hu­man pri­mate…pre­clin­i­cal stud­ies THOR-707 at dos­es ten times high­er than the dos­es ob­served to max­i­mal­ly ex­pand CD8+ T cells in NHP did not re­sult in signs of VLS, as mea­sured by in­creas­es in eosinophil count and lung and liv­er weight. Pub­lished pre­clin­i­cal lit­er­a­ture shows that com­bin­ing IL-2 treat­ment with PD-1 in­hibitors could have syn­er­gis­tic ef­fects in en­hanc­ing CD8+ T cell re­spons­es. As a re­sult, we be­lieve that THOR-707 in com­bi­na­tion with im­mune check­point in­hibitors may have greater an­ti-tu­mor ef­fects than PD-1 in­hibitors alone with­out the VLS ob­served with aldesleukin.

There’s al­so an­oth­er IL-2 pro­gram that works in re­verse, pro­mot­ing reg­u­la­to­ry T cells that sup­press the im­mune sys­tem to the ad­van­tage of pa­tients suf­fer­ing from au­toim­mune dis­ease.

Nek­tar’s NK­TR-214 is spot­light­ed as the biggest ri­val in the clin­ic. But the S-1 al­so cites Roche’s RO6874281, which spurred 3 ob­jec­tive re­spons­es in an ear­ly study. That drug, they say, is sim­i­lar to their own. And there is al­so Alk­er­mes’ ALKS-4230, “where a por­tion of the al­pha re­cep­tor is at­tached to IL-2, which dis­ables al­pha bind­ing. In a Phase I study of ad­vanced sol­id tu­mors, no re­spons­es were ob­served in 24 pa­tients.”

Jay Lichter’s Aval­on still con­trols the largest batch of stock, with 32%, with Pe­ter Kolchin­sky at RA Cap­i­tal in for 28.2% and Or­biMed hold­ing 21.5%. Those are the big 3. Shawver her­self has a slight 1% of the eq­ui­ty. Tighe Rear­don, the CFO at Aval­on, has 6.5% of the shares.

Biotech Half­time Re­port: Af­ter a bumpy year, is biotech ready to re­bound?

The biotech sector has come down firmly from the highs of February as negative sentiment takes hold. The sector had a major boost of optimism from the success of the COVID-19 vaccines, making investors keenly aware of the potential of biopharma R&D engines. But from early this year, clinical trial, regulatory and access setbacks have reminded investors of the sector’s inherent risks.

RBC Capital Markets recently surveyed investors to take the temperature of the market, a mix of specialists/generalists and long-only/ long-short investment strategies. Heading into the second half of the year, investors mostly see the sector as undervalued (49%), a large change from the first half of the year when only 20% rated it as undervalued. Around 41% of investors now believe that biotech will underperform the S&P500 in the second half of 2021. Despite that view, 54% plan to maintain their position in the market and 41% still plan to increase their holdings.

NYU surgeon transplants an engineered pig kidney into the outside of a brain-dead patient (Joe Carrotta/NYU Langone Health)

No, sci­en­tists are not any clos­er to pig-to-hu­man trans­plants than they were last week

Steve Holtzman was awoken by a 1 a.m. call from a doctor at Duke University asking if he could put some pigs on a plane and fly them from Ohio to North Carolina that day. A motorcyclist had gotten into a horrific crash, the doctor explained. He believed the pigs’ livers, sutured onto the patient’s skin like an external filter, might be able to tide the young man over until a donor liver became available.

UP­DAT­ED: Agenus calls out FDA for play­ing fa­vorites with Mer­ck, pulls cer­vi­cal can­cer BLA at agen­cy's re­quest

While criticizing the FDA for what may be some favoritism towards Merck, Agenus on Friday officially pulled its accelerated BLA for its anti-PD-1 inhibitor balstilimab as a potential second-line treatment for cervical cancer because of the recent full approval for Merck’s Keytruda in the same indication.

The company said the BLA, which was due for an FDA decision by Dec. 16, was withdrawn “when the window for accelerated approval of balstilimab closed,” thanks to the conversion of Keytruda’s accelerated approval to a full approval four months prior to its PDUFA date.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 120,400+ biopharma pros reading Endpoints daily — and it's free.

How to col­lect and sub­mit RWD to win ap­proval for a new drug in­di­ca­tion: FDA spells it out in a long-await­ed guid­ance

Real-world data are messy. There can be differences in the standards used to collect different types of data, differences in terminologies and curation strategies, and even in the way data are exchanged.

While acknowledging this somewhat controlled chaos, the FDA is now explaining how biopharma companies can submit study data derived from real-world data (RWD) sources in applicable regulatory submissions, including new drug indications.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

David Lockhart, ReCode Therapeutics CEO

Pfiz­er throws its weight be­hind LNP play­er eye­ing mR­NA treat­ments for CF, PCD

David Lockhart did not see the meteoric rise of messenger RNA and lipid nanoparticles coming.

Thanks to the worldwide fight against Covid-19, mRNA — the genetic code that can be engineered to turn the body into a mini protein factory — and LNPs, those tiny bubbles of fat carrying those instructions, have found their way into hundreds of millions of people. Within the biotech world, pioneers like Alnylam and Intellia have demonstrated just how versatile LNPs can be as a delivery vehicle for anything from siRNA to CRISPR/Cas9.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 120,400+ biopharma pros reading Endpoints daily — and it's free.

René Russo, Xilio CEO (Alicia Petitti for Xilio)

Xilio Ther­a­peu­tics goes pub­lic as bio­phar­ma IPOs rum­ble for­ward in Q4

It’s been a busy fall on Wall Street — and this week, we’ve got another biotech going public after Ventyx yesterday.

Massachusetts solid-tumor biotech Xilio Therapeutics made its public debut today, joining 149 other biotechs that have gone public so far this year.

Back on October 1st, Xilio filed its S-1 with the SEC to make its IPO debut for $100 million — the next step in financing after completing a $95 million Series C back in February.

Luc Boblet, Egle Therapeutics CEO

A new Treg play­er emerges with $46M and back­ing from Take­da

In recent years, the chorus of biotechs and Big Pharma backers targeting regulatory T cells — also known as “Tregs” — for cancer and autoimmune diseases has only grown louder.

The newest voice is from Egle Therapeutics, which sang out a $46.4 million Series A round on Friday led by LSP and Bpifrance through their InnoBio 2 fund. Takeda’s venture arm also chipped in, about a year after the pharma struck a research pact with the Paris-based upstart.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 120,400+ biopharma pros reading Endpoints daily — and it's free.

Marty Duvall, Oncopeptides CEO

On­copep­tides stock craters as it pulls can­cer drug Pepax­to from the mar­ket

Shares of Oncopeptides crashed more than 70% in early Friday trading after the company said it’s pulling its multiple myeloma drug Pepaxto (melphalan flufenamide) from the US market after failing a confirmatory trial. The move will force the company to close its US and EU business units and enact significant layoffs.

The FDA had scheduled an adcomm meeting next Thursday to discuss Pepaxto, which first won accelerated approval in February and costs about $19,000 per course of treatment. The committee was to weigh in on whether the confirmatory trial demonstrated a worse overall survival in the treatment arm compared to the control arm.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 120,400+ biopharma pros reading Endpoints daily — and it's free.

Pfiz­er pitch­es its Covid-19 vac­cine for younger chil­dren ahead of ad­comm next week

Pfizer will present its case to the FDA’s vaccine adcomm next week, seeking authorization for a lower-dose version of its Covid-19 vaccine for kids ages 5 through 12, which the Biden administration said will likely begin rolling out early next month.

Two primary doses of the 10 µg vaccine (the dose for those ages 12 and up is 30 μg) given 3 weeks apart in this group of children “have shown a favorable safety and tolerability profile, robust immune responses against all variants of concern including Delta, and vaccine efficacy of 90.7% against laboratory-confirmed symptomatic COVID-19,” the company said in briefing documents ahead of next Tuesday’s meeting of the FDA’s Vaccines and Related Biological Products Advisory Committee.